Publicacións nas que colabora con Carmen Burgaleta Alonso de Ozalla (7)

2017

  1. Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea

    Haematologica, Vol. 102, Núm. 1, pp. 103-109

2016

  1. Current opinion and consensus statement regarding the diagnosis, prognosis, and treatment of patients with essential thrombocythemia: a survey of the Spanish Group of Ph-negative Myeloproliferative Neoplasms (GEMFIN) using the Delphi method

    Annals of Hematology, Vol. 95, Núm. 5, pp. 719-732

  2. Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera

    British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793

2015

  1. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months

    Cancer Medicine, Vol. 4, Núm. 7, pp. 995-1002

2014

  1. Do chronic myeloid leukemia patients with late “warning” responses benefit from “watch and wait” or switching therapy to a second generation tyrosine kinase inhibitor?

    American Journal of Hematology, Vol. 89, Núm. 11, pp. E206-E211

1990

  1. Hematological abnormalities in hemophilic patients with human immunodeficiency virus infection

    American Journal of Hematology, Vol. 33, Núm. 4, pp. 230-233

1987

  1. Granulopoietic precursors in hemophiliac patients infected by HTLV-III/LAV.

    American journal of clinical pathology